ATE231886T1 - Kreisförmig permutierte liganden und kreisförmig permutierte chimärische molekülen - Google Patents

Kreisförmig permutierte liganden und kreisförmig permutierte chimärische molekülen

Info

Publication number
ATE231886T1
ATE231886T1 AT95916319T AT95916319T ATE231886T1 AT E231886 T1 ATE231886 T1 AT E231886T1 AT 95916319 T AT95916319 T AT 95916319T AT 95916319 T AT95916319 T AT 95916319T AT E231886 T1 ATE231886 T1 AT E231886T1
Authority
AT
Austria
Prior art keywords
pct
circular permutated
ligands
chimeric molecules
permutated
Prior art date
Application number
AT95916319T
Other languages
English (en)
Inventor
Ira Pastan
Robert J Kreitman
Raj Puri
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE231886T1 publication Critical patent/ATE231886T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
AT95916319T 1994-04-08 1995-04-07 Kreisförmig permutierte liganden und kreisförmig permutierte chimärische molekülen ATE231886T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/225,224 US5635599A (en) 1994-04-08 1994-04-08 Fusion proteins comprising circularly permuted ligands
PCT/US1995/004468 WO1995027732A2 (en) 1994-04-08 1995-04-06 Circularly permuted ligands and circularly permuted chimeric molecules

Publications (1)

Publication Number Publication Date
ATE231886T1 true ATE231886T1 (de) 2003-02-15

Family

ID=22844038

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95916319T ATE231886T1 (de) 1994-04-08 1995-04-07 Kreisförmig permutierte liganden und kreisförmig permutierte chimärische molekülen

Country Status (8)

Country Link
US (2) US5635599A (de)
EP (1) EP0754192B1 (de)
AT (1) ATE231886T1 (de)
AU (1) AU694211B2 (de)
CA (1) CA2187283C (de)
DE (1) DE69529517T2 (de)
ES (1) ES2190451T3 (de)
WO (1) WO1995027732A2 (de)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5635599A (en) * 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
US5891680A (en) * 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
PL184424B1 (pl) * 1995-10-05 2002-10-31 Searle & Co Agoniści krwiotwórczych receptorów wieloczynnościowych
US6066318A (en) * 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
JP2000513924A (ja) * 1995-10-05 2000-10-24 ジー．ディー．サール アンド カンパニー 新規ｃ−ｍｐｌ受容体アゴニスト
AU717733B2 (en) * 1995-10-05 2000-03-30 G.D. Searle & Co. Novel G-CSF receptor agonists
US6100070A (en) * 1995-10-05 2000-08-08 G. D. Searle & Co. G-CSF receptor agonists
US5986059A (en) 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
US6335426B1 (en) 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists
US6319504B1 (en) 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
IL129158A0 (en) * 1996-09-30 2000-02-17 Exseed Genetics L L C Encapsulation of polypeptides within the starch matrix
US5969105A (en) * 1996-10-25 1999-10-19 Feng; Yiqing Stem cell factor receptor agonists
US6660257B1 (en) 1996-10-25 2003-12-09 Pharmacia Corporation Circular permuteins of flt3 ligand
JP2001503266A (ja) * 1996-10-25 2001-03-13 ジー．ディー．サール アンド カンパニー 環状に並べ替えたエリスロポイエチン受容体アゴニスト
WO1998017810A2 (en) * 1996-10-25 1998-04-30 G.D. Searle & Co. Multi-functional chimeric hematopoietic receptor agonists
US6967092B1 (en) 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
US5994104A (en) * 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
US20030054012A1 (en) * 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
US7314632B1 (en) * 1997-07-11 2008-01-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pseudomonas exotoxin A-like chimeric immunogens
ES2249838T3 (es) * 1997-07-11 2006-04-01 The Government Of The Usa As Represented By The Secretary Of The Depar. Of Health And Human Services Inmunogenos quimericos similares a la exotoxina a de pseudomonas.
BR9815493A (pt) * 1997-07-21 2000-10-31 Pharmacia & Upjohn Ab Citólise dirigida de células-alvo, agentes e composições que causam citólise, e compostos que podem ser usados para produzir os agentes
GB9724838D0 (en) * 1997-11-26 1998-01-21 Franks Christopher R Compositions
AU3380099A (en) * 1998-04-03 1999-10-25 University Of Washington Circularly permuted biotin binding proteins
DE19819846B4 (de) * 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
MXPA01012165A (es) * 1999-05-27 2003-06-30 Celltek Biotechnologies Inc Antagonistas ccr3 del receptor de quimiocina.
US7994278B1 (en) 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
ATE425180T1 (de) * 2000-12-21 2009-03-15 Us Gov Health & Human Serv Ein chimäres protein das nichttoxische pseudomonas exotoxin a und typ iv pilin sequenzen enthält
WO2003006501A2 (en) 2001-07-11 2003-01-23 Maxygen Holdings, Ltd. G-csf conjugates
JP2005508375A (ja) * 2001-11-09 2005-03-31 ネオファーム、インコーポレイティッド Ｉｌ−１３を発現する腫瘍の選択的治療
AU2003213647A1 (en) * 2002-02-27 2003-09-09 Emory University Multimeric binding complexes
WO2003077838A2 (en) * 2002-03-05 2003-09-25 National Institutes Of Health Office Of Technology Transfer Hiv-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and immunogens
US7208594B2 (en) * 2002-06-29 2007-04-24 Aquanova Ag Isoflavone concentrates as well as methods for their production
US7166574B2 (en) 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US8227411B2 (en) * 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
US7598224B2 (en) 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US7074561B2 (en) * 2002-10-22 2006-07-11 Biomerieux, Inc. Isothermal amplification based assay for the detection and quantitation of alpha-fetoprotein mRNA
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
WO2004087758A2 (en) * 2003-03-26 2004-10-14 Neopharm, Inc. Il 13 receptor alpha 2 antibody and methods of use
GB0315182D0 (en) * 2003-06-28 2003-08-06 Asterion Ltd Cytokine variant polypeptides
US7414028B1 (en) 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US7671012B2 (en) 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
US20080227696A1 (en) * 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
US7528105B1 (en) 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
EP1725576B1 (de) * 2004-02-20 2010-09-22 Biosurface Engineering Technologies, Inc. Positiver modulator des knochenmorphogenetisches protein-2 (bmp-2)
IL161673A0 (en) 2004-04-29 2004-09-27 Applied Research Systems Compositions and methods for therapy of chemotherapy-induced neuropathy
CA2580501A1 (en) * 2004-09-16 2006-03-30 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
WO2006041906A2 (en) 2004-10-04 2006-04-20 Trinity Biosystems, Inc. Methods and compositions for immunizing against pseudomonas infection
KR20070089996A (ko) 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법
WO2006086607A2 (en) * 2005-02-10 2006-08-17 Emory University Novel proteins with enhanced functionality and methods of making novel proteins using circular permutation
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
MX2007013430A (es) * 2005-04-29 2008-03-19 Univ California Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria.
RU2007149238A (ru) 2005-06-01 2009-07-20 Максиджен Холдингз Лтд. (Ky) Пегилированные полипептиды гксф и способы их получения
GB0606946D0 (en) * 2006-04-06 2006-05-17 Asterion Ltd Polypeptide antagonist
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
EP2046350A4 (de) * 2006-06-22 2011-09-14 Biosurface Eng Tech Inc Zusammensetzungen und verfahren zur freisetzung eines bmp-2-amplifikators/coaktivators für verstärkte osteogenese
AU2007264672B2 (en) 2006-06-28 2013-03-14 Hadasit Medical Research Services & Development Ltd Caspase-8 and inflammation, infection and wound healing
WO2009014835A2 (en) * 2007-06-21 2009-01-29 Angelica Therapeutics, Inc. Modified toxins
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
AU2008296478B9 (en) * 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
CA2698357C (en) * 2007-09-04 2017-06-06 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
EP2268297A4 (de) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc Modifizierte toxine
CN102083600A (zh) * 2008-06-02 2011-06-01 恩蒂循环有限责任公司 多余的轮胎及橡胶复合物再加工
US20110171219A1 (en) * 2008-09-19 2011-07-14 Fahar Merchant Treating cancer stem cells using targeted cargo proteins
US20100183545A1 (en) * 2008-10-14 2010-07-22 The United States Of America, As Represented By The Secretary, Targeted cargo protein combination therapy
US20160354472A1 (en) * 2010-10-22 2016-12-08 Protox Therapeutics Corp. Use of human serum albumin to decrease antigenicity of therapeutic proteins
JP6093712B2 (ja) 2010-12-22 2017-03-08 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン２のスーパーアゴニストおよびアンタゴニスト
WO2013112871A1 (en) 2012-01-27 2013-08-01 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic il-13 polypeptides
AU2015268652B2 (en) * 2012-06-08 2017-11-23 Mural Oncology, Inc. Ligands modified by circular permutation as agonists and antagonists
LT3401402T (lt) * 2012-06-08 2020-12-28 Alkermes Pharma Ireland Limited Ligandai, modifikuoti cirkuliarinės permutacijos pagalba, kaip agonistai ir antagonistai
US9738696B2 (en) 2012-08-09 2017-08-22 The Board Of Trustees Of The Leland Stanford Junior University Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities
WO2014066443A1 (en) * 2012-10-23 2014-05-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
CA2902905A1 (en) 2013-03-15 2014-09-25 Claude Geoffrey Davis Modified toxins
KR102512797B1 (ko) 2013-09-05 2023-03-22 에이비2 바이오 에스에이 염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ)
WO2015042707A1 (en) 2013-09-24 2015-04-02 Medicenna Therapeutics Pte Ltd Interleukin-2 fusion proteins and uses thereof
JP6936934B2 (ja) 2013-09-24 2021-09-22 メディシナ セラピューティクス インコーポレイテッド インターロイキン−４受容体結合融合タンパク質及びその使用
WO2015061573A1 (en) 2013-10-23 2015-04-30 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compounds that bind to human immunodeficiency virus rev response element
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
AU2015298263B2 (en) 2014-07-31 2020-05-14 Anji Pharmaceuticals, Inc. ApoE mimetic peptides and higher potency to clear plasma cholesterol
SG11201706879UA (en) 2015-03-05 2017-09-28 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP7433051B2 (ja) 2017-06-19 2024-02-19 メディシナ セラピューティクス インコーポレイテッド Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法
WO2019051204A1 (en) 2017-09-08 2019-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SYNERGISTIC COMBINATION OF IL4, INTERFERON GAMMA AND INTERFERON ALPHA RECEPTOR AGENTS FOR USE IN THE TREATMENT OF OVARIAN CANCER
AU2018347796B2 (en) 2017-10-10 2025-07-24 Medicenna Therapeutics, Inc. IL-4-fusion formulations for treatment of central nervous system (CNS) tumors
US20200299349A1 (en) 2017-11-21 2020-09-24 The Board Of Trustees Of The Leland Stanford Junior University Partial agonists of interleukin-2
WO2019239213A2 (en) 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
PT4065585T (pt) 2019-11-25 2025-09-30 Alkermes Inc Compostos macrocíclicos substituídos e métodos de tratamento relacionados
CA3166509A1 (en) 2020-01-14 2021-07-22 Synthekine, Inc. Biased il2 muteins methods and compositions
EP4146174A1 (de) 2020-05-06 2023-03-15 AB2 Bio SA Il-18-bindendes protein (il-18bp) bei atemwegserkrankungen
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
TW202231663A (zh) * 2020-12-22 2022-08-16 大陸商江蘇恆瑞醫藥股份有限公司 抗ｉｌ－４ｒ抗體或其抗原結合片段的複合物及醫藥用途
CN117440972A (zh) 2021-03-24 2024-01-23 奥克梅斯公司 Upar抗体和具有所述抗体的融合蛋白
US20260008830A1 (en) * 2022-01-28 2026-01-08 Fundació Centre De Regulació Genòmica Therapeutic cytokines and methods
EP4486367A1 (de) 2022-03-04 2025-01-08 AB2 Bio SA Il-18-bindendes protein (il-18bp) zur behandlung von vexas
WO2023215432A1 (en) 2022-05-04 2023-11-09 Promega Corporation Circularly permuted dehalogenase variants
WO2023215452A2 (en) 2022-05-04 2023-11-09 Promega Corporation Split modified dehalogenase variants
EP4519425A1 (de) 2022-05-04 2025-03-12 Promega Corporation Modifizierte dehalogenase mit erweiterten oberflächenschleifenregionen
CN117003852B (zh) * 2022-07-07 2024-11-05 北京大学 白细胞介素-2的拓扑改造及其作为自身免疫病药物的应用
WO2024261235A1 (en) 2023-06-22 2024-12-26 Ablynx Nv Chimeric proteins for modulating cytokine receptor activity
WO2025132880A1 (en) 2023-12-19 2025-06-26 Vib Vzw Transmembrane beta barrels
WO2026038145A1 (en) 2024-08-13 2026-02-19 Ab2 Bio Sa Il-18 binding protein (il-18bp) and methods of using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
KR900005995A (ko) * 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5635599A (en) * 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands

Also Published As

Publication number Publication date
DE69529517T2 (de) 2003-11-06
US5635599A (en) 1997-06-03
US6011002A (en) 2000-01-04
ES2190451T3 (es) 2003-08-01
AU2285795A (en) 1995-10-30
CA2187283A1 (en) 1995-10-19
AU694211B2 (en) 1998-07-16
EP0754192B1 (de) 2003-01-29
WO1995027732A3 (en) 1996-05-02
CA2187283C (en) 2008-09-23
WO1995027732A2 (en) 1995-10-19
EP0754192A1 (de) 1997-01-22
DE69529517D1 (de) 2003-03-06

Similar Documents

Publication Publication Date Title
ATE231886T1 (de) Kreisförmig permutierte liganden und kreisförmig permutierte chimärische molekülen
PT724456E (pt) Anticorpos contra cd4
PL331405A1 (en) Modified ligands of tie-2 receptor
NL300238I1 (de)
ATE327329T1 (de) Tie ligand-homologuen
DK1144472T3 (da) Vandige reaktive spartelmasser (II)
ATE544776T1 (de) Chimäre dna-bindeproteine
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
NO20001556L (no) Kontrastmidler for infarkt- og nekroseavbildning
AU2002239792A1 (en) Phosphonite ligands, catalyst compositions and hydroformylation process utilizing same
TW284777B (de)
DE59709869D1 (de) Neue substanzbibliothek und damit hergestellte supramolekulare komplexe
DE69515528D1 (de) Infusionspumpe für medizinische flüssigkeiten
ATE193007T1 (de) Multifunktionelle vernetzungsreagenzien für haemoglobin und vernetzte haemoglobinconjugate
AU2001291771A1 (en) Cycloaliphatic/aromatic diphosphines and use thereof in catalysis
DE69715418D1 (de) Liganden für asymmetrische katalysen
ATE229819T1 (de) Pseudopolyrotaxane
MY134247A (en) Bidentate ligands for the carbonylation of unsaturated compounds
ATE428500T1 (de) Kunststoff-geträgerte phosphorliganden verwendbar in der katalyse
DE59303446D1 (de) Neue bis-phenyl-hexene
ID27733A (id) Metoksiminofenilasetamida
UA66851C2 (uk) Фурилфосфіни, металоорганічні комплекси на їх основі, способи їх одержання і каталізатори
MY131703A (en) Complexes of the lanthanides with heterocyclic carbenes
Silverstein Finger-pointing stalls Superfund.
MX9504154A (es) Composicion que emulsiona, encapsula y dispersa un hidrocarburo o un solvente.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0754192

Country of ref document: EP